Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK.
BMC Infect Dis. 2022 Sep 3;22(1):722. doi: 10.1186/s12879-022-07705-8.
Dengue is a neglected tropical disease, for which no therapeutic agents have shown clinical efficacy to date. Clinical trials have used strikingly variable clinical endpoints, which hampers reproducibility and comparability of findings. We investigated a delta modified Sequential Organ Failure Assessment (delta mSOFA) score as a uniform composite clinical endpoint for use in clinical trials investigating therapeutics for moderate and severe dengue.
We developed a modified SOFA score for dengue, measured and evaluated its performance at baseline and 48 h after enrolment in a prospective observational cohort of 124 adults admitted to a tertiary referral hospital in Vietnam with dengue shock. The modified SOFA score included pulse pressure in the cardiovascular component. Binary logistic regression, cox proportional hazard and linear regression models were used to estimate association between mSOFA, delta mSOFA and clinical outcomes.
The analysis included 124 adults with dengue shock. 29 (23.4%) patients required ICU admission for organ support or due to persistent haemodynamic instability: 9/124 (7.3%) required mechanical ventilation, 8/124 (6.5%) required vasopressors, 6/124 (4.8%) required haemofiltration and 5/124 (4.0%) patients died. In univariate analyses, higher baseline and delta (48 h) mSOFA score for dengue were associated with admission to ICU, requirement for organ support and mortality, duration of ICU and hospital admission and IV fluid use.
The baseline and delta mSOFA scores for dengue performed well to discriminate patients with dengue shock by clinical outcomes, including duration of ICU and hospital admission, requirement for organ support and death. We plan to use delta mSOFA as the primary endpoint in an upcoming host-directed therapeutic trial and investigate the performance of this score in other phenotypes of severe dengue in adults and children.
登革热是一种被忽视的热带病,迄今为止,尚无治疗药物显示出临床疗效。临床试验使用了差异极大的临床终点,这阻碍了研究结果的再现性和可比性。我们研究了 delta 改良序贯器官衰竭评估(delta mSOFA)评分,作为一种用于治疗中度和重度登革热的治疗药物的临床试验的统一综合临床终点。
我们为登革热开发了改良 SOFA 评分,在越南一家三级转诊医院对 124 名因登革热休克入院的成年患者进行前瞻性观察队列研究,在入组时和入组后 48 小时测量并评估其表现。改良 SOFA 评分在心血管成分中包括脉压。使用二元逻辑回归、Cox 比例风险和线性回归模型来估计 mSOFA 和 delta mSOFA 与临床结局之间的关联。
分析包括 124 名患有登革热休克的成年人。29 名(23.4%)患者需要 ICU 入住以进行器官支持或由于持续的血流动力学不稳定:124 名患者中有 9 名(7.3%)需要机械通气,124 名患者中有 8 名(6.5%)需要血管加压药,124 名患者中有 6 名(4.8%)需要血液滤过,124 名患者中有 5 名(4.0%)患者死亡。在单变量分析中,较高的基线和 delta(48 小时)mSOFA 评分与入住 ICU、器官支持和死亡率、ICU 和住院时间以及静脉输液使用有关。
登革热的基线和 delta mSOFA 评分能够很好地区分登革热休克患者的临床结局,包括 ICU 和住院时间、器官支持和死亡的需求。我们计划在即将进行的宿主定向治疗试验中使用 delta mSOFA 作为主要终点,并研究该评分在成人和儿童重度登革热其他表型中的表现。